Article DOI: http://doi.org/10.3201/eid3010.231650

EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.

## Rapid Decision Algorithm for Patient Triage during Ebola Outbreaks

## Appendix

## Method for Employing the Algorithm

The method for using the algorithm (Figure 3) was as follows: a patient with any of the four "priority" variables was considered as high-risk of infection (C category) regardless of his/her score ("prioritization rule"). The EVD-prediction score (right-side of the tool) was computed by summing up the individual scores of each sign, symptom, or exposure history noted as "present", after which the A/B/C categorization followed the thresholds indicated on the bottom-left; the rational choice of these thresholds is explained in the result section.

## **Characteristics of the Testing Population**

The testing population consisted of 14,346 new EVD-suspected patients, including 2,618 children under 5 (18.3%), notified between August 15, 2019, and November 27, 2019, of whom 319 were confirmed EVD-positive. The confirmation rate was therefore 2.2%, around 3.6 times lower than that observed in the testing dataset. As with the modeling population, there was a higher positivity rate among late presenters than among early presenters (109/6993 = 1.6% if notified within days 0-2 of symptoms, versus 154/6765, 2.3% if notified at day 3 after onset or later).

In this testing population, 1140/11500 patients (9.9%) had had contact with a known EVD case, among whom the RT-PCR confirmation rate was 13.4%. In the other subjects, the confirmation rate was only 0.6%. The confirmation rate in the presence of the other three priority variables was also higher than in their absence (contact with a traditional practitioner: 7.1% vs. 1.7%; bleeding at the injection site: 17.6% vs. 2.2%; bleeding from the gums: 24.4% vs. 2.2%).

Finally, logistic regression showed a profile broadly similar to that obtained in the modeling phase (*22*): among patients notified within the first two days following symptom onset, contact with a known EVD case (OR = 4.0, IC95%: 1.7-10.1), recent attendance at a funeral (OR = 2.6, IC95% = 1.4-5.0), contact with a health care facility (OR = 2.3, IC95%: 0.9-5.1), bleeding gums (OR = 23.8, IC95% = 0. 8-317), and asthenia (OR = 2.9, IC95% = 1.5-6.0) were positive predictors of infection, while abdominal pain (OR = 0.3, IC95% = 01-0.6) was a negative predictor. Among patients notified 3 days or more after the onset of symptoms, contact with an EVD case (OR = 27.2, IC95% : 16.3-45.9), a health facility (OR = 4.6, IC95% : 2.7-7.5) and a traditional practitioner (OR = 3.4, IC95% : 1.0-9.6) positively predicted infection, as did bleeding at the injection site (OR = 144, IC95% : 1.9-3.1238), conjunctivitis (OR = 8.2, IC95% : 3.5-18.4), nausea/vomiting (OR = 1.6, IC95% : 1.0-2.6), vomiting of blood (OR = 3.4, IC95% : 1.2-3.8), throat pain (OR = 2.6, IC95%: 1.2-5.4) and muscle/joint pain (OR = 1.7, IC95%: 1.0-3.0). Conversely, cough (OR = 0.6, IC95%: 0.4-1.0) and headache (OR = 0.6, IC95%: 0.4-1.0) were negative predictors in late presenters.

	Time-to-																		
Variable	presentation	Sensitiv	vity (95%)	CI)	Specific	city (95%)	CI)	<b>PPV</b> (95	5%CI)		NPV (95			LR+ (9	95%CI)		LR- (9	95%CI)	
Abdominal pain	Any	46.7%	44.4%	49.0%	43.7%	43.1%	44.4%	6.8%	6.3%	7.2%	90.4%	89.8%	90.9%	0.8	0.8	0.9	1.2	1.2	1.3
Anorexia	Any	70.2%	68.0%	72.2%	36.7%	36.0%	37.3%	8.8%	8.4%	9.3%	93.4%	92.8%	93.9%	1.1	1.1	1.1	0.8	0.8	0.9
Asthenia	Any	80.6%	78.8%	82.4%	31.2%	30.6%	31.8%	9.2%	8.8%	9.7%	94.9%	94.3%	95.4%	1.2	1.1	1.2	0.6	0.6	0.7
Any bleeding	Any	14.5%	12.9%	16.2%	86.1%	85.7%	86.6%	8.3%	7.3%	9.3%	92.1%	91.7%	92.5%	1.0	0.9	1.2	1.0	1.0	1.0
Bleeding epistaxis	Any	3.0%	2.3%	3.9%	96.1%	95.8%	96.3%	6.9%	5.2%	8.9%	91.2%	90.8%	91.6%	0.8	0.6	1.0	1.0	1.0	1.0
Bleeding gums	Any	3.9%	3.0%	4.9%	99.5%	99.4%	99.6%	43.7%	35.8%	51.8%	91.5%	91.1%	91.9%	8.1	5.9	11.0	1.0	1.0	1.0
Bleeding hemoptisis	Any	0.9%	0.5%	1.5%	98.9%	98.8%	99.1%	7.5%	4.3%	11.9%	91.2%	90.8%	91.6%	0.8	0.5	1.4	1.0	1.0	1.0
Bleeding injection site	Any	2.0%	1.4%	2.8%	99.9%	99.9%	100.0%	70.6%	56.2%	82.5%	91.4%	91.0%	91.8%	25.0	13.7	45.5	1.0	1.0	1.0
Bleeding melena	Any	4.0%	3.2%	5.1%	93.9%	93.5%	94.2%	5.9%	4.6%	7.4%	91.1%	90.7%	91.5%	0.7	0.5	0.8	1.0	1.0	1.0
Bleeding other	Any	1.8%	1.3%	2.6%	98.8%	98.7%	99.0%	12.6%	8.8%	17.2%	91.6%	91.2%	92.0%	1.6	1.1	2.2	1.0	1.0	1.0
Bleeding urine	Any	0.6%	0.3%	1.0%	99.1%	98.9%	99.2%	5.4%	2.6%	9.7%	91.2%	90.8%	91.6%	0.6	0.3	1.1	1.0	1.0	1.0
Bleeding vagina	Any	2.2%	1.6%	3.0%	96.2%	95.9%	96.5%	5.4%	3.9%	7.2%	91.1%	90.7%	91.5%	0.6	0.4	0.8	1.0	1.0	1.0
Bleeding vomito	Any	0.8%	0.5%	1.4%	99.5%	99.4%	99.6%	13.9%	8.0%	21.9%	91.2%	90.8%	91.6%	1.7	1.0	2.9	1.0	1.0	1.0
negro	Ану	0.070	0.370	1.470	33.370	33.470	33.070	13.370	0.070	21.370	J1.2/0	30.070	31.070	1.7	1.0	2.5	1.0	1.0	1.0
-	Δου	3.5%	2.7%	4.5%	97.6%	97.4%	97.8%	12.4%	9.6%	15.6%	91.3%	90.9%	91.7%	1.5	1.1	1.9	1.0	1.0	1.0
Bleeding	Any	3.5%	2.170	4.0%	31.0%	91.470	91.070	12.470	9.070	10.0%	51.5%	90.9%	91.170	1.5	1.1	1.9	1.0	1.0	1.0
nematemesis	A m. (	40.00/	0.40/	10.00/	00.09/	00.60/	00 50/	0.00/	7.00/	10.20/	04 70/	01 20/	02 10/		0.0	10	4.0	1.0	1.0
Breathlessness	Any	10.8%	9.4%	12.3%	90.0%	89.6%	90.5%	9.0%	7.9%	10.3%	91.7%	91.3%	92.1%	1.1	0.9	1.2	1.0 0.9	1.0	1.0
Chest pain	Any	21.5%	19.7%	23.5%	84.4%	83.8%	84.8%	11.1%	10.1%	12.2%	92.2%	91.8%	92.6%	1.4	1.3	1.5		0.9	1.0
Coma	Any	2.0%	1.4%	2.8%	98.3%	98.1%	98.4%	9.6%	6.9%	13.0%	91.6%	91.3%	92.0%	1.2	0.8	1.6	1.0	1.0	1.0
Confusion,	Any	3.1%	2.3%	4.0%	98.6%	98.4%	98.7%	16.5%	12.7%	20.8%	91.8%	91.4%	92.1%	2.2	1.6	2.9	1.0	1.0	1.0
disorientation																			
Conjunctivitis	Any	9.2%	7.9%	10.6%	97.4%	97.2%	97.6%	24.6%	21.4%	28.0%	92.1%	91.8%	92.5%	3.6	3.0	4.2	0.9	0.9	0.9
Cough	Any	18.8%	17.0%	20.7%	69.3%	68.6%	69.9%	5.1%	4.6%	5.7%	90.6%	90.1%	91.1%	0.6	0.6	0.7	1.2	1.1	1.2
Contact EVD case	Any	65.4%	63.1%	67.7%	83.9%	83.4%	84.4%	25.2%	23.9%	26.5%	96.7%	96.4%	97.0%	4.1	3.9	4.3	0.4	0.4	0.4
Contact funeral	Any	34.4%	32.1%	36.7%	92.6%	92.2%	92.9%	26.7%	24.9%	28.7%	94.7%	94.4%	95.0%	4.6	4.3	5.0	0.7	0.7	0.7
Contact health facility	Any	27.3%	25.1%	29.5%	90.1%	89.7%	90.5%	17.9%	16.4%	19.4%	94.0%	93.7%	94.3%	2.8	2.5	3.0	0.8	0.8	0.8
Contact informal	Any	3.2%	2.4%	4.2%	99.0%	98.8%	99.1%	19.3%	14.8%	24.6%	92.9%	92.6%	93.2%	3.1	2.3	4.1	1.0	1.0	1.0
nealer																			
Diarrhea	Any	40.4%	38.2%	42.7%	62.9%	62.2%	63.5%	8.9%	8.3%	9.5%	92.2%	91.8%	92.6%	1.1	1.0	1.2	0.9	0.9	1.0
Eyes: light sensitvity	Any	2.2%	1.6%	3.0%	98.5%	98.3%	98.6%	11.5%	8.4%	15.4%	91.7%	91.3%	92.1%	1.4	1.0	2.0	1.0	1.0	1.0
Fever	Any	49.6%	47.3%	51.9%	48.8%	48.1%	49.4%	7.7%	7.2%	8.2%	91.8%	91.3%	92.3%	1.0	0.9	1.0	1.0	1.0	1.1
Headache	Any	53.1%	50.8%	55.4%	38.3%	37.6%	38.9%	7.0%	6.6%	7.4%	90.4%	89.7%	91.0%	0.9	0.8	0.9	1.2	1.2	1.3
Hiccups	Any	4.3%	3.4%	5.4%	97.4%	97.1%	97.6%	13.0%	10.4%	15.9%	91.8%	91.4%	92.1%	1.6	1.3	2.1	1.0	1.0	1.0
laundice	Any	3.5%	2.7%	4.4%	97.4%	97.1%	97.6%	10.8%	8.4%	13.6%	91.7%	91.3%	92.1%	1.3	1.0	1.7	1.0	1.0	1.0
loint pain	Any	45.1%	42.8%	47.4%	63.7%	63.0%	64.4%	10.0%	9.3%	10.6%	92.9%	92.4%	93.3%	1.2	1.2	1.3	0.9	0.8	0.9
Myalgia	Any	38.1%	35.9%	40.4%	71.7%	71.1%	72.4%	10.8%	10.0%	11.5%	92.8%	92.4%	93.2%	1.3	1.3	1.4	0.9	0.8	0.9
Other symptoms	Any	9.6%	8.1%	11.4%	89.9%	89.4%	90.4%	7.8%	6.5%	9.2%	91.8%	91.4%	92.3%	0.9	0.8	1.1	1.0	1.0	1.0
Petechia purpura	Any	0.4%	0.2%	0.8%	99.8%	99.8%	99.9%	19.4%	8.2%	36.0%	91.3%	90.9%	91.6%	2.5	1.1	5.7	1.0	1.0	1.0
Rash	Any	4.0%	3.2%	5.1%	96.8%	96.6%	97.1%	10.5%	8.3%	12.9%	91.7%	91.3%	92.1%	1.3	1.0	1.6	1.0	1.0	1.0
Dysphagia	Any	18.6%	16.9%	20.5%	90.7%	90.3%	91.1%	15.4%	13.9%	17.0%	92.4%	92.1%	92.8%	2.0	1.8	2.2	0.9	0.9	0.9
Sore throat	Any	15.7%	14.1%	17.4%	92.9%	92.6%	93.3%	16.8%	15.1%	18.7%	92.4%	92.0%	92.8%	2.2	2.0	2.5	0.9	0.9	0.9
/omiting. nausea	Any	50.6%	48.3%	52.9%	49.5%	48.8%	50.1%	8.2%	7.7%	8.7%	91.9%	91.3%	92.0 <i>%</i> 92.4%	1.0	1.0	1.0	1.0	1.0	1.0
<u> </u>																			
Abdominal pain	Days 0-2	27.6%	23.8%	31.7%	45.2%	44.3%	46.2%	2.6%	2.2%	3.0%	92.3%	91.5%	93.1%	0.5	0.4	0.6	1.6	1.5	1.7
Anorexia	Days 0-2	53.8%	49.4%	58.1%	41.0%	40.1%	42.0%	4.6%	4.1%	5.1%	94.4%	93.7%	95.1%	0.9	0.8	1.0	1.1	1.0	1.2
Asthenia	Days 0-2	70.0%	65.9%	73.9%	35.8%	34.9%	36.7%	5.4%	4.8%	5.9%	95.8%	95.1%	96.4%	1.1	1.0	1.2	0.8	0.7	1.0
Any bleeding	Days 0-2	6.9%	4.9%	9.5%	87.4%	86.7%	88.0%	2.8%	2.0%	3.8%	94.8%	94.3%	95.2%	0.6	0.4	0.8	1.1	1.0	1.1
Bleeding epistaxis	Days 0-2	1.0%	0.3%	2.3%	96.3%	95.9%	96.7%	1.5%	0.5%	3.5%	94.4%	93.9%	94.9%	0.3	0.1	0.6	1.0	1.0	1.0

Appendix Table 1. Diagnostic performance of individual variables for the prediction of Ebola infection (Training dataset)

Ţ	Time-to-																		
	presentation		<b>/ity</b> (95%0			ity (95%)		<b>PPV</b> (95			NPV (95			LR+ (9			<b>LR-</b> (9		
00	Days 0-2	0.8%	0.2%	2.0%	99.6%	99.5%	99.7%	10.8%	3.0%	25.4%	94.6%	94.1%	95.0%	2.1	0.7	5.9	1.0	1.0	1.0
0 1	Days 0-2	0.2%	0.0%	1.1%	99.3%	99.1%	99.5%	1.6%	0.0%	8.8%	94.5%	94.0%	95.0%	0.3	0.0	2.1	1.0	1.0	1.0
	Days 0-2	0.0%	0.0%	0.7%	100.0%	99.9%	100.0%	0.0%	0.0%	70.8%	94.5%	94.0%	95.0%	0.0	0.0	NA	1.0	1.0	1.0
5	Days 0-2	1.2%	0.4%	2.6%	95.2%	94.7%	95.6%	1.4%	0.5%	3.1%	94.4%	93.9%	94.9%	0.3	0.1	0.6	1.0	1.0	1.0
Bleeding other D	Days 0-2	1.8%	0.8%	3.3%	98.8%	98.5%	99.0%	7.6%	3.5%	13.9%	94.8%	94.3%	95.2%	1.5	0.7	2.9	1.0	1.0	1.0
0	Days 0-2	0.2%	0.0%	1.1%	99.2%	99.0%	99.4%	1.4%	0.0%	7.7%	94.5%	94.0%	95.0%	0.3	0.0	1.8	1.0	1.0	1.0
Bleeding vagina E	Days 0-2	2.0%	1.0%	3.6%	95.8%	95.4%	96.3%	2.7%	1.3%	4.9%	94.4%	93.9%	94.9%	0.5	0.3	0.9	1.0	1.0	1.0
Bleeding vomito E	Days 0-2	0.4%	0.0%	1.4%	99.7%	99.5%	99.8%	6.3%	0.8%	20.8%	94.5%	94.0%	95.0%	1.1	0.3	4.8	1.0	1.0	1.0
negro																			
Bleeding E	Days 0-2	1.2%	0.4%	2.6%	98.0%	97.7%	98.3%	3.4%	1.3%	7.3%	94.5%	94.0%	95.0%	0.6	0.3	1.4	1.0	1.0	1.0
hematemesis																			
Breathlessness E	Days 0-2	7.0%	4.9%	9.5%	92.1%	91.6%	92.7%	4.6%	3.3%	6.3%	94.8%	94.3%	95.2%	0.9	0.6	1.2	1.0	1.0	1.0
Chest pain E	Days 0-2	12.8%	10.0%	16.0%	87.4%	86.7%	88.1%	5.2%	4.0%	6.6%	94.9%	94.4%	95.4%	1.0	0.8	1.3	1.0	1.0	1.0
Coma E	Days 0-2	1.2%	0.4%	2.5%	98.3%	98.0%	98.6%	3.6%	1.3%	7.7%	94.8%	94.3%	95.2%	0.7	0.3	1.6	1.0	1.0	1.0
Confusion, E	Days 0-2	0.8%	0.2%	2.0%	99.0%	98.8%	99.2%	4.0%	1.1%	10.0%	94.8%	94.4%	95.2%	0.8	0.3	2.1	1.0	1.0	1.0
disorientation																			
	Days 0-2	6.2%	4.3%	8.7%	97.4%	97.0%	97.7%	11.5%	8.0%	15.8%	95.0%	94.5%	95.4%	2.4	1.7	3.4	1.0	0.9	1.0
Cough E	Days 0-2	18.0%	14.8%	21.6%	72.9%	72.0%	73.8%	3.4%	2.8%	4.2%	94.3%	93.8%	94.9%	0.7	0.6	0.8	1.1	1.1	1.2
Contact EVD case E	Days 0-2	80.2%	76.3%	83.7%	80.3%	79.5%	81.1%	17.1%	15.6%	18.7%	98.8%	98.5%	99.0%	4.1	3.8	4.3	0.2	0.2	0.3
Contact funeral E	Days 0-2	37.8%	33.3%	42.3%	91.9%	91.4%	92.5%	18.2%	15.8%	20.8%	96.9%	96.5%	97.2%	4.7	4.1	5.4	0.7	0.6	0.7
Contact health facility E	Days 0-2	21.5%	17.9%	25.6%	91.7%	91.1%	92.2%	10.9%	8.9%	13.1%	96.1%	95.7%	96.5%	2.6	2.1	3.1	0.9	0.8	0.9
Contact informal	Days 0-2	1.3%	0.5%	2.9%	99.4%	99.3%	99.6%	9.8%	3.7%	20.2%	95.6%	95.2%	96.0%	2.4	1.0	5.4	1.0	1.0	1.0
healer																			
	Days 0-2	24.6%	20.9%	28.5%	63.1%	62.2%	64.1%	3.4%	2.9%	4.1%	94.0%	93.4%	94.6%	0.7	0.6	0.8	1.2	1.1	1.3
, ,	Days 0-2	3.5%	2.1%	5.5%	98.4%	98.2%	98.7%	10.8%	6.6%	16.6%	94.9%	94.5%	95.4%	2.2	1.4	3.6	1.0	1.0	1.0
	Days 0-2	53.0%	48.5%	57.4%	50.1%	49.1%	51.1%	5.2%	4.6%	5.9%	95.3%	94.7%	95.9%	1.1	1.0	1.2	0.9	0.9	1.0
	Days 0-2	50.7%	46.3%	55.0%	40.4%	39.5%	41.4%	4.2%	3.8%	4.8%	94.0%	93.3%	94.7%	0.9	0.8	0.9	1.2	1.1	1.3
•	Days 0-2	2.0%	0.9%	3.6%	98.1%	97.8%	98.4%	5.4%	2.6%	9.7%	94.8%	94.4%	95.3%	1.0	0.6	2.0	1.0	1.0	1.0
	Days 0-2	1.6%	0.7%	3.0%	98.2%	97.9%	98.4%	4.5%	2.0%	8.7%	94.8%	94.3%	95.2%	0.9	0.4	1.7	1.0	1.0	1.0
	Days 0-2	37.7%	33.5%	42.0%	67.2%	66.3%	68.2%	5.8%	5.0%	6.6%	95.3%	94.8%	95.8%	1.1	1.0	1.3	0.9	0.9	1.0
, ,	Days 0-2	29.8%	25.9%	34.0%	75.0%	74.1%	75.8%	6.0%	5.1%	7.0%	95.2%	94.7%	95.7%	1.2	1.0	1.4	0.9	0.9	1.0
- 71	Days 0-2	9.9%	7.0%	13.5%	89.5%	88.8%	90.2%	4.7%	3.3%	6.5%	95.0%	94.4%	95.5%	0.9	0.7	1.3	1.0	1.0	1.0
	Days 0-2	0.0%	0.0%	0.7%	99.9%	99.8%	100.0%	0.0%	0.0%	33.6%	94.5%	94.0%	95.0%	0.0	0.0	NA	1.0	1.0	1.0
	Days 0-2	3.3%	1.9%	5.2%	97.2%	96.9%	97.5%	6.1%	3.6%	9.6%	94.8%	94.4%	95.3%	1.2	0.7	1.9	1.0	1.0	1.0
	Days 0-2	6.0%	4.1%	8.5%	91.9%	91.4%	92.5%	3.9%	2.7%	5.5%	94.7%	94.3%	95.2%	0.7	0.5	1.1	1.0	1.0	1.0
	Days 0-2	6.1%	4.2%	8.5%	93.5%	93.0%	94.0%	4.8%	3.3%	6.7%	94.9%	94.4%	95.3%	0.9	0.7	1.3	1.0	1.0	1.0
V	Days 0-2	35.1%	31.0%	39.4%	50.8%	49.8%	51.8%	3.6%	3.1%	4.2%	93.7%	93.0%	94.3%	0.7	0.6	0.8	1.3	1.2	1.4
•	≥ Day 3	54.6%	51.8%	57.3%	42.9%	41.9%	43.8%	10.7%	9.9%	11.5%	88.3%	87.4%	89.2%	1.0	0.9	1.0	1.1	1.0	1.1
	≥ Day 3	77.0%	74.6%	79.3%	32.8%	31.9%	33.8%	12.5%	11.7%	13.2%	92.0%	91.1%	92.9%	1.1	1.1	1.2	0.7	0.6	0.8
	≥ Day 3	85.3%	83.2%	87.2%	27.6%	26.7%	28.5%	12.7%	12.0%	13.4%	93.8%	92.9%	94.6%	1.2	1.1	1.2	0.5	0.5	0.6
	≥ Day 3	17.2%	15.2%	19.4%	86.2%	85.5%	86.8%	13.4%	11.7%	15.1%	89.4%	88.7%	90.0%	1.2	1.1	1.4	1.0	0.9	1.0
0 1	≥ Day 3	3.9%	2.9%	5.2%	96.4%	96.0%	96.8%	12.9%	9.6%	16.7%	88.0%	87.4%	88.7%	1.1	0.8	1.5	1.0	1.0	1.0
00	≥ Day 3	4.9%	3.8%	6.3%	99.6%	99.4%	99.7%	60.0%	49.7%	69.7%	88.5%	87.8%	89.1%	11.0	7.4	16.3	1.0	0.9	1.0
5 1	≥ Day 3	1.1%	0.6%	1.9%	98.7%	98.5%	98.9%	10.9%	6.1%	17.7%	88.0%	87.3%	88.6%	0.9	0.5	1.6	1.0	1.0	1.0
0,	≥ Day 3	2.9%	2.0%	4.0%	99.9%	99.8%	99.9%	77.8%	62.9%	88.8%	88.3%	87.6%	88.9%	25.6	12.7	51.6	1.0	1.0	1.0
5	≥ Day 3	4.9%	3.8%	6.3%	93.7%	93.2%	94.2%	9.5%	7.4%	12.1%	87.9%	87.2%	88.6%	0.8	0.6	1.0	1.0	1.0	1.0
0	≥ Day 3	1.9%	1.2%	2.8%	98.9%	98.7%	99.1%	18.1%	11.8%	25.9%	88.5%	87.9%	89.1%	1.7	1.1	2.6	1.0	1.0	1.0
Bleeding urine ≥	≥ Day 3	0.6%	0.2%	1.2%	99.0%	98.8%	99.2%	7.4%	3.0%	14.6%	88.0%	87.3%	88.6%	0.6	0.3	1.3	1.0	1.0	1.0

	Time-to-													/					
Variable	presentation		vity (95%)			city (95%)		<b>PPV</b> (95			NPV (95				95%CI)		LR- (9		
Bleeding vagina	≥ Day 3	2.4%	1.6%	3.4%	96.6%	96.2%	97.0%	8.8%	5.9%	12.3%	87.9%	87.3%	88.6%	0.7	0.5	1.0	1.0	1.0	1.0
Bleeding vomito	≥ Day 3	1.0%	0.5%	1.7%	99.5%	99.3%	99.6%	20.3%	11.0%	32.8%	88.0%	87.4%	88.7%	1.9	1.0	3.5	1.0	1.0	1.0
negro																			
Bleeding	≥ Day 3	4.5%	3.4%	5.8%	97.7%	97.4%	98.0%	21.4%	16.5%	26.9%	88.2%	87.6%	88.8%	2.0	1.5	2.7	1.0	1.0	1.0
hematemesis																			
Breathlessness	≥ Day 3	12.2%	10.4%	14.1%	88.0%	87.4%	88.7%	11.6%	9.9%	13.5%	88.6%	87.9%	89.2%	1.0	0.9	1.2	1.0	1.0	1.0
Chest pain	≥ Day 3	24.8%	22.5%	27.3%	81.5%	80.7%	82.3%	14.7%	13.3%	16.3%	89.4%	88.7%	90.0%	1.3	1.2	1.5	0.9	0.9	1.0
Coma	≥ Day 3	2.3%	1.5%	3.2%	98.3%	98.0%	98.5%	14.4%	9.8%	20.2%	88.6%	87.9%	89.2%	1.3	0.9	1.9	1.0	1.0	1.0
Confusion,	≥ Day 3	3.8%	2.8%	5.0%	98.3%	98.1%	98.6%	22.7%	17.2%	29.0%	88.7%	88.1%	89.3%	2.3	1.6	3.1	1.0	1.0	1.0
disorientation	-																		
Conjunctivitis	≥ Day 3	10.3%	8.7%	12.2%	97.4%	97.1%	97.7%	34.0%	29.3%	39.0%	89.3%	88.7%	89.9%	4.0	3.2	4.9	0.9	0.9	0.9
Cough	≥ Day 3	19.2%	17.0%	21.4%	66.6%	65.7%	67.5%	6.7%	5.9%	7.6%	86.8%	86.0%	87.5%	0.6	0.5	0.6	1.2	1.2	1.3
Contact EVD case	≥ Day 3	58.8%	55.9%	61.7%	86.4%	85.6%	87.0%	33.9%	31.8%	36.0%	94.6%	94.1%	95.1%	4.3	4.0	4.6	0.5	0.4	0.5
Contact funeral	≥ Day 3	32.7%	30.0%	35.6%	92.9%	92.3%	93.4%	34.2%	31.4%	37.1%	92.4%	91.9%	92.9%	4.6	4.1	5.1	0.7	0.7	0.8
Contact health facility	≥ Day 3	30.1%	27.4%	32.9%	88.1%	87.5%	88.7%	22.4%	20.3%	24.6%	91.7%	91.1%	92.3%	2.5	2.3	2.8	0.8	0.8	0.8
Contact informal	≥ Day 3	3.9%	2.9%	5.2%	98.6%	98.3%	98.8%	23.9%	17.9%	30.7%	90.0%	89.5%	90.6%	2.8	2.0	3.9	1.0	1.0	1.0
healer																			
Diarrhea	≥ Day 3	46.6%	43.8%	49.3%	63.6%	62.6%	64.5%	14.0%	12.9%	15.1%	90.3%	89.6%	91.0%	1.3	1.2	1.4	0.8	0.8	0.9
Eyes : light sensitvity	≥ Day 3	1.7%	1.0%	2.6%	98.5%	98.2%	98.7%	12.7%	8.1%	18.8%	88.5%	87.9%	89.1%	1.1	0.7	1.8	1.0	1.0	1.0
Fever	≥ Day 3	47.2%	44.4%	50.0%	50.0%	49.0%	51.0%	10.4%	9.6%	11.2%	88.5%	87.7%	89.3%	0.9	0.9	1.0	1.1	1.0	1.1
Headache	≥ Day 3	54.2%	51.4%	57.0%	36.4%	35.5%	37.3%	9.6%	8.9%	10.3%	86.5%	85.4%	87.5%	0.9	0.8	0.9	1.3	1.2	1.3
Hiccups	≥ Day 3	5.1%	4.0%	6.5%	96.8%	96.4%	97.1%	17.3%	13.5%	21.5%	88.7%	88.1%	89.3%	1.6	1.2	2.1	1.0	1.0	1.0
Jaundice	≥ Day 3	4.3%	3.3%	5.6%	96.5%	96.2%	96.9%	14.0%	10.7%	17.9%	88.6%	88.0%	89.2%	1.3	0.9	1.7	1.0	1.0	1.0
Joint pain	≥ Day 3	48.1%	45.3%	50.9%	59.9%	59.0%	60.9%	13.2%	12.2%	14.2%	90.2%	89.4%	90.9%	1.2	1.1	1.3	0.9	0.8	0.9
Myalgia	≥ Day 3	41.4%	38.6%	44.2%	68.5%	67.6%	69.4%	14.3%	13.1%	15.4%	90.2%	89.5%	90.9%	1.3	1.2	1.4	0.9	0.8	0.9
Other symptoms	≥ Day 3	9.7%	7.8%	11.9%	89.4%	88.7%	90.1%	10.5%	8.5%	12.8%	88.6%	87.8%	89.3%	0.9	0.7	1.1	1.0	1.0	1.0
Petechia purpura	≥ Day 3	0.4%	0.1%	1.0%	99.8%	99.7%	99.9%	26.3%	9.1%	51.2%	88.0%	87.4%	88.7%	2.6	0.9	7.3	1.0	1.0	1.0
Rash	≥ Day 3	4.3%	3.3%	5.6%	96.5%	96.1%	96.8%	13.8%	10.5%	17.6%	88.6%	88.0%	89.2%	1.2	0.9	1.6	1.0	1.0	1.0
Dysphagia	≥ Day 3	23.7%	21.3%	26.1%	89.5%	88.9%	90.1%	22.6%	20.4%	25.0%	90.1%	89.5%	90.7%	2.3	2.0	2.5	0.9	0.8	0.9
Sore throat	≥ Day 3	19.8%	17.6%	22.1%	92.4%	91.8%	92.9%	25.1%	22.4%	27.9%	89.9%	89.3%	90.5%	2.6	2.3	3.0	0.9	0.8	0.9
Vomiting. nausea	≥ Day 3	56.7%	53.9%	59.4%	49.4%	48.5%	50.4%	12.4%	11.6%	13.3%	90.0%	89.2%	90.8%	1.1	1.1	1.2	0.9	0.8	0.9

	Time-to-		Versio	on of the a	algorithm	n and ind	lividual s	cores for	r each pro	edictor	
Predictor	presentation	OR	4.1	4.2	4.3	4.4	4.5	4.21	4.22	4.23	4.24
Diarrhea	Days 0-2	NS	-2	-1	0	0	-1	-1	-2	-1	-1
	≥ Day 3	1.6	+2	+1	+2	+1	+1	+1	+2	+1	+1
Asthenia	Days 0-2	1.9	+2	+1	+2	+1	+1	+1	+3	+1	+1
	≥ Day 3	1.9	+2	+1	+2	+1	+1	+1	+3	+1	+1
Myalgia	Days 0-2	NS	0	0	-	-	-	0	0	-	0
	≥ Day 3	1.3	+1	+1	-	-	-	+1	+1	-	+1
Anorexia	Days 0-2	NS	-	-	-	-	-	-	0	-	0
	≥ Day 3	1.7	-	-	-	-	-	-	+1	-	+1
Abdominal pain	Days 0-2	0.4	-2	-1	-2	-1	-1	-1	-3	-2	-2
	≥ Day 3	0.8	0	0	0	0	0	0	0	0	0
Headache	Days 0-2	0.7	-2	-1	-2	-1	-1	-1	-	-	-1
	≥ Day 3	0.6	-2	-1	-2	-1	-1	-1	-	-	-1
Conjunctivitis	Days 0-2	NS	+3	+1	0	0	0	+1	0	+1	+1
	≥ Day 3	2.4	+3	+1	+3	+1	+2	+1	+2	+2	+2
Sore throat	Days 0-2	NS	+2	+1	0	0	0	+1	0	0	0
	≥ Day 3	1.8	+2	+1	+3	+1	+2	+2	+3	+2	+2
Dysphagia	Days 0-2	NS	0	0	0	0	0	0	0	-	0
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	≥ Day 3	1.8	+2	+1	+1	+1	+1	+2	+1	-	+1
Cough	Days 0-2	NS	0	0	0	0	0	0	0	0	0
Ū	≥ Day 3	0.5	-3	-1	-3	-1	-1	-1	-1	-1	-1
Melena	Days 0-2	NS	0	0	0	0	0	0	-	0	0
	≥ Day 3	0.4	-4	-1	-3	-1	-1	-1	-	-1	-1
Hematemesis	Days 0-2	NS	0	0	-	-	-	0	0	-	0
	≥ Day 3	1.5	+2	+1	-	-	-	+1	+1	-	+1
Consultation at a	Days 0-2	2.1	0	0	0	0	0	0	0	0	0
health facility (MoH)	≥ Day 3	2.4	+2	+1	+3	+1	+1	+2	+2	+2	+2
Attended a funeral	Days 0-2	2.1	+3	+1	+3	+1	+1	+2	+3	+2	+2
	≥ Day 3	1.9	+2	+1	0	0	0	+1	+3	+1	+1

Appendix Table 2. Nine versions of the algorithm applied to the testing dataset, with different predictor combinations and various individual scores.\*

\* The final version of the algorithm presented in the article (Figure 3) is equivalent to version 4.2. OR, Odds ratio, based on logistic regression diagnostics (training dataset); NS, not significant.

Appendix Table 3. Performance (AUROC) of nine versions of the algorithm to predict Ebola infection, for early presenters (0-2	2
days)*	

			Standard		
Rank	Version	AUROC	deviation	Lower value	Upper value
1	algo_4.21	0.7385	0.0534	0.7194	0.7576
2	algo_4.23	0.7300	0.0334	0.7178	0.7417
3	algo_4.24	0.7287	0.0432	0.7132	0.7441
4	algo_4.2 §	0.7136	0.0439	0.6978	0.7293
5	algo_4.22	0.7091	0.0530	0.6901	0.7280
6	algo_4.1	0.7033	0.0508	0.6851	0.7215
7	algo_4.5	0.6700	0.0469	0.6530	0.6865
8	algo_4.3	0.6645	0.0407	0.6500	0.6791
9	algo_4.4	0.6536	0.04239	0.6383	0.6687
* The final v	ersion of the algorithm	presented in the arti	cle (Figure 2) is equiv	alent to version 4.2.	

Appendix Table 4. Performance (AUROC) of nine versions of the algorithm to predict Ebola infection, for late presenters (≥3 days)\*

			Standard		
Rank	Version	AUROC	deviation	Lower value	Upper value
1	algo_4.1	0.7446	0.0417	0.7297	0.7595
2	algo_4.24	0.7395	0.0295	0.7290	0.7501
3	algo_4.21	0.7367	0.0334	0.7248	0.7487
4	algo_4.2 §	0.7333	0.0291	0.7229	0.7437
5	algo_4.22	0.7324	0.0352	0.7198	0.7450
6	algo_4.3	0.7283	0.0290	0.7180	0.7387
7	algo_4.5	0.7218	0.0297	0.7112	0.7324
8	algo_4.23	0.7210	0.0384	0.7072	0.7348
9	algo 4.4	0.7062	0.0242	0.6975	0.7149


\* The final version of the algorithm presented in the article (Figure 2) is equivalent to version 4.2.

**Appendix Table 5.** Distribution of priority variables by EVD status (EVD- or EVD+). The testing population (14,346 EVD-suspected patients) is stratified in three categories: "absence of priority variables", "absence of priority variables", "at least one priority variable". Within the prioritized subset ("at least one priority variable"), the proportion of each of the four priority variables is shown.


Category	Proportion in EVD- stratum (%)	Proportion in EVD+ stratum (%)	Overall proportion (%)
Absence of priority variables	66.7% (9,361/14,027)	15.7% (50/319)	65.6% (9,411/14,346)
Unknown (absence of priority variables but at least one missing value)	25.2% (3,532/14,027)	31.7% (101/319)	25.3% (3,633/14,346)
At least one priority variable	8.1% (1,134/14,027)	52.7% (168/319)	9.1% (1,302/14,346)
Total	100%	100%	100%
Contact with an EVD case	8.7% (987/11,285)	71.2% (153/215)	9.9% (1,140/11,500)
Contact with an informal healer	1.0% (118/12,222)	4.1% (9/219)	0.9% (127/12,441)
Bleeding at the injection site	0.1% (14/12,749)	1.0% (3/290)	0.1% (17/13,039)
Bleeding gums	0.2% (31/12,758)	3.4% (10/290)	0.3% (41/13,048)

Appendix Table 6. Age and sex distributions among EVD-suspected patients included in the 2 prospective substudies

		Sub-study	
Category	Beni, 2020	Equateur, 2020	Total
No strata	2217	449	2666
Age group			
0-5 years	496 (20.8%)	130 (29.3%)	626 (23.6%)
6-12 years	672 (28.2%)	83 (18.7%)	755 (28.4%)
13-25 years	410 (19.7%)	62 (14.0%)	472 (17.8%)
>25 years	634 (26.6%)	169 (38.1%)	803 (30.2%)
Sex			
Female	1091 (49.6%)	231 (52.1%)	1322 (50.0%)
Male	1109 (50.4%)	212 (47.9%)	1321 (50.0%)
Time-to-registration (from onset, in			
days)			
0-2	885 (40.0%)	157 (34.4%)	1032 (38.8%)
3-5	964 (43.6%)	184 (42.3%)	1148 (43.2%)
≥ 6	363 (16.1%)	116 (25.4%)	479 (18.0%)
Vaccination status upon evaluation			
Not vaccinated	1118 (50.9%)	341 (76.1%)	1459 (55.2%)
Vaccinated without card	1062 (48.3%)	95 (21.2%)	1157 (43.7%)
Vaccinated, with card	17 (0.8%)	12 (2.7%)	29 (1.1%)



**Appendix Figure 1.** Diagnostic performance of the newly developed algorithm (version 4.2, all components) with those of 3 previously developed versions. All 4 algorithms were applied on the same testing population (see Methods section). Classification performance was evaluated using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and likelihood ratios of positive (LR+) and negative tests (LR–).



**Appendix Figure 2.** Inclusion dates of EVD-suspected patients in the prospective substudies (10th and 11th epidemics in the Democratic Republic of the Congo).